|
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years Clinical research trials and A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years. A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 2 Years/18 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - (All of these criteria must be met in order to be eligible to participate in this study) - Females of child-bearing potential must have a negative pregnancy test at screening and on Day 1 and must agree to use a proven barrier method of contraception (e.g., spermicide plus condom). Note: hormonal contraceptives (e.g., birth control pills, Norplant, etc.) are not considered a sufficient form of contraception for this study. - Parent or legal guardian (and study patient if possible) has the ability to understand what is required of the patient in the study, what will occur during the study, and provide written informed consent to participate. - Screening lab result of plasma HIV-1 RNA greater than or equal to 400 copies/mL. - Must be able to use 2 nucleoside reverse transcriptase inhibitors as a background regimen. - Exclusion Criteria: - No prior history of having received AGENERASE. - No use of non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy within 14 days of study Day 1 or anticipated need for concurrent NNRTI therapy during the study period. - Cannot have had an AIDS defining illness (acute CDC Category C event) within 28 days of screening. - Cannot be pregnant or breast-feeding. - Additional qualifying criteria to be determined by the physician.
Total Enrollment:
Location and Contact Information:
Study Site
Milan, , 20122
Italy
Study Site
Madrid, , 28046
Spain
Study Site
Richmond, Virginia, 23219
United States
Study Site
Verona, , 37126
Italy
Study Site
Modena, , 41100
Italy
Study Site
New York City, New York, 10016
United States
Study Site
Chicago, Illinois, 60614
United States
Study Site
Cleveland, Ohio, 44106
United States
Study Site
Bucharest, ,
Romania
Study Site
London, , WC1N 1EH
United Kingdom
Study Site
New York City, New York, 10021
United States
Study Site
Los Angeles, California, 90033
United States
Study Site
Milan, , 20142
Italy
Study Site
Bucharest, ,
Romania
Study Site
Genoa, , 16147
Italy
Study Site
Malaga, , 29010
Spain
Study Site
Padua, , 35128
Italy
Study Site
Rome, , 00165
Italy
Study Site
Chapel Hill, North Carolina, 27599
United States
Study Site
Syracuse, New York, 13120
United States
Study Site
St. Petersburg, Florida, 33701
United States
Study Site
Durham, North Carolina, 27705
United States
Study Site
Cordoba, , 14004
Spain
Study Site
Amadora, , 2700-276
Portugal
Study Site
Bucharest, ,
Romania
Study Site
London, , W2 1NY
United Kingdom
Study Site
Barcelona, , 08950
Spain
Study Site
Lisbon, , 1150
Portugal
Study Site
Barcelona, , 08035
Spain
Study Site
Los Angeles, California, 90027
United States
Study Site
Stony Brook, New York, 11794
United States
Study Site
Lisboa, , 1649-035
Portugal
Study Site
Montreal, Quebec, H3T 1C5
Canada
Study Site
Florence, , 50132
Italy
Study Site
Ft. Worth, Texas, 76104
United States
Study Site
Toronto, Ontario, M5G 1X8
Canada
Study Site
New Orleans, Louisiana, 70112
United States
Study Site
Boston, Massachusetts, 02118
United States
Study Site
Birmingham, Alabama, 35233
United States
Study Site
Bronx, New York, 10461
United States
Study Site
Jacksonville, Florida, 32209
United States
Study Site
Seville, , 410113
Spain
Study Site
Pavia, , 27100
Italy
Study Site
New York City, New York, 10029
United States
Study Site
Rotterdam, , 3015 GJ
Netherlands
Study Site
Dallas, Texas, 75235
United States
Study Site
London, , SW17 0QT
United Kingdom
Study Site
Madrid, , 28007
Spain
Study Site
Madrid, , 28041
Spain
Additional Information:
Study ID Numbers: APV 20003;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040664
Other Hiv Infections Studies:
1. A Comparison of HIV-Infected Patients with and without Opportunistic (AIDS-Related) Infection
2. A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children
3. HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs
4. A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma
5. A Study of Saquinavir Soft Gelatin Capsules Combined with Other Anti-HIV Drugs in HIV-1 Infected Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Amadora Clinical Trials
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years
|
|
|
|
|
|
|
|